News and Announcements
Intermin Releases Initial Driling Results from Olympia and Baden Powell
- Published August 31, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Intermin Resources Limited (ASX:IRC) is pleased to announce the initial drilling results from the reverse circulation and aicore drilling at the 100% owned Baden Powell and Olympia gold prospects.
KEY TAKEAWAYS:
- First pass drilling completed at the 100% owned Baden Powell and Olympia prospects at the Bardoc Tectonic Zone 60kms north of Kalgoorlie-Boulder
- Reverse circulation drilling at the Baden Powell prospect focused on extensions
- The drilling has confirmed increasing tenor at depth in this area with follow up and step out drilling planned for the December Quarter
- Follow up drilling at Olympia will now focus on two key area to test both the quartz sulphide mineralisation at depth for the presence of a larger supergene blanket
- Dimond and RC drilling continues at multiple prospects in the Kalgoorlie region with results expected throughout the remainder of the 2017 calendar year
Commenting on results, Intermin’s Managing Director, Mr Jon Price said:
“The high grade intercept at Baden Powell is very encouraging and demonstrates the increasing widths and grades at depth to the south of the historic workings where very little drilling has been conducted in the past.
This is also the first ever drilling at Olympia in our understanding and it is extremely pleasing to see anomalous gold mineralisation supporting the gold in soils work completed last year.
The Company is investing heavily in new discovery exploration this year and will continue to apply the very latest in since and technology to systematically expand on the results to date.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
